Budget impact analysis of rituximab biosimilar in Italy from the hospital and payer perspectives
Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish · 2018
DOI: 10.1177/2284240318784289 ↗Kurz gefasst
Fachartikel in der Zeitschrift Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish, 2018. Verfasst von Carla Rognoni und 2 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Sandoz Italia Spa.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Förderung
- Sandoz Italia Spa
Zitieren
APA
Rognoni, C., Bertolani, A., & Jommi, C. (2018). Budget impact analysis of rituximab biosimilar in Italy from the hospital and payer perspectives. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish. https://doi.org/10.1177/2284240318784289
Vancouver
Rognoni C, Bertolani A, Jommi C. Budget impact analysis of rituximab biosimilar in Italy from the hospital and payer perspectives. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish. 2018. doi:10.1177/2284240318784289
BibTeX
@article{Rognoni2018,
author = {Rognoni, Carla and Bertolani, Arianna and Jommi, Claudio},
title = {Budget impact analysis of rituximab biosimilar in Italy from the hospital and payer perspectives},
journal = {Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish},
year = {2018},
doi = {10.1177/2284240318784289}
}
EUVIMED